Cached score snapshot

US.RVTY · Revvity

110分制 56.5/110;5D動能v2 4/50;排序分 60.5/160

Ranking score 60.5/160
Main score 56.5/110
5D momentum v2 4/50
Rank #332
Setup grade F 28.4

Score breakdown

觀望

Elevated twelvedata

Score and price trend

F 28.4 Elevated risk

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 07-16 09-18 10-21 11-05 11-19 $95.99$142.26$188.53 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.644 · anchors 120 +0.97% -0.92% / +3.24% 60% 5% Actual +1.92% · vs median +0.95% · inside 25-75 band
30D observation +3.60% -2.16% / +12.41% 67.5% 17.5% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.51% -1.31% / +2.85% 55.6% 7.5% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-07-16 → 2026-11-19 · 177 archived points · 6 Improving turn signal · 5 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 60.5
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 56.5/110 (觀望)
5D momentum v2 4/50 (弱)
Score with momentum v2 60.5/160 (低排序)
Risk level Elevated

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 146.6695
ma50 131.2764
close 152.16
prevClose 153.6
avgVolume20 2353670
volumeRatio 0.62
changePercent -0.94

Metrics snapshot

close 152.16
volume 1456900
changePercent -0.94

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 56.5/110
Main rating 觀望
5D momentum v2 4/50
Score with momentum v2 60.5/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 2.4/5 · 較差

Dimension score 2.4/5
Dimension grade 較差

Sub-items

pbPoints 0.5
pePoints 0.2
epsPoints 0
roePoints 0
debtPoints 0.5
marginPoints 0
turnoverUsdM 221.6819
volumePoints 0.5
revenuePoints 0
dividendPoints 0.3
marketCapPoints 0.4

資金流 — 13.2/20 · 一般

Dimension score 13.2/20
Dimension grade 一般

Sub-items

cmfPoints 2.4
mfiPoints 2.4
obvPoints 2.4
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.RVTY
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 10.8/15 · 良好

Dimension score 10.8/15
Dimension grade 良好

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 15.08

trend

score 4

details

qqq

ma20 735.722
ma50 723.169
name QQQ
close 747.58
points 2

spy

ma20 767.263
ma50 766.8368
name SPY
close 773.93
points 2
source twelvedata+fred
atrPct 4.0521
atrPoints 2
cciPoints 2.4
vixPoints 2.4
marketTrendPoints 4

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 5.7/10 · 較差

Dimension score 5.7/10
Dimension grade 較差

Sub-items

position

score 1.1

details

atrPct 4.0521
turnoverUsdM 221.6819
liquidityPoints 0.4
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.RVTY
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 139.8286

strength_details

ma_score 1.5
atr_score 1
rsi_score 3
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 8.1
take_profit_price 164.8511
target_multiplier 1.9
technical_strength 1.63
take_profit_percent 8.3
positionPoints 1.1
stopLossPoints 1.2

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 8.1042
diversificationPoints 2

技術信號 — 18.4/30 · 一般

Dimension score 18.4/30
Dimension grade 一般

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 0.9
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 0.9
vcp_reason 站上MA50;升放量(近10日2日);Ready=N;Confirm=N

vcp_metrics

up_days 6
vol_ref 2159530
down_days 3
vcp_ready false
above_ma50 true
avg_vol_10 2221880
avg_vol_20 2348025
avg_vol_30 2159530
range_pct_10 0.1608
range_pct_20 0.298
range_pct_30 0.298
up_expand_ok true
lookback_used 59
near_20d_high false
contraction_ok false
down_shrink_ok false
up_expand_days 2
breakout_20d_ok false
vol_ratio_10_30 1.0289
dist_to_20d_high 0.0848
down_shrink_days 1
breakout_level_20d 166.25
vcp_breakout_confirm false
contraction_ratio_10_30 0.5394
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0.4
shortMacdPoints 0.4
volConfirmPoints 1
volumePointsTechnical 0.4

情緒分析 — 4/10 · 較差

Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 2
sentimentScoreRaw 0.6

sentimentData

raw {"id":142592011,"url":"https://finnhub.io/api/news?id=1354c9a3ac86acca82d61b1988ec9d31e1f0743e2810cf95605e1c46072883de","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).","category":"company","datetime":1790953202,"headline":"Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?"}, {"id":142499577,"url":"https://finnhub.io/api/news?id=ff4832de7ba97e9983ed854de2a013c27c693bf0523e62c4715efc273d08445c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.","category":"company","datetime":1790700002,"headline":"Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?"}, {"id":142423965,"url":"https://finnhub.io/api/news?id=a9ff4d3ba263b75cc7992bb9bb5763803e41a2e984ca6e0e139ac9d5b22bbd62","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.","category":"company","datetime":1790341740,"headline":"RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection"}, {"id":142350477,"url":"https://finnhub.io/api/news?id=cb58c8c8f2b541bcd7567cd8dc86f2dd0998a2a24d9e4da3258e8a9c57c37605","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...","category":"company","datetime":1790129530,"headline":"Why Revvity (RVTY) Is Getting Attention Today"}, {"id":142188758,"url":"https://finnhub.io/api/news?id=03b1bbe1a346d39ced2120c20af628767c205f491c25a175a480c992424683c9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.","category":"company","datetime":1789550040,"headline":"Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?"}, {"id":142162217,"url":"https://finnhub.io/api/news?id=c9e230170d179b85b200d044ccc0f27596b9851ed1649e5e94f0dc70a6ee1f7d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.","category":"company","datetime":1789479331,"headline":"Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks"}, {"id":142164499,"url":"https://finnhub.io/api/news?id=a187851a3b32d0f518cf6a22cdf7cb457662bd37fcebf1db3d2d732edf49b488","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"RVTY","summary":"Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...","category":"company","datetime":1789473097,"headline":"Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript"}, {"id":142138505,"url":"https://finnhub.io/api/news?id=69174abc8d26e7ed40432acacd43de7ef7c90e09eac260583ae38c53c0592293","image":"","source":"SeekingAlpha","related":"RVTY","summary":"","category":"company","datetime":1789385497,"headline":"Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"}
raw_source {"id":142728921,"url":"https://finnhub.io/api/news?id=0dd7d1b383dd91d4ef55e272b4d0e25c1c563ddef68dfa481dcf459a3f0016fa","image":"https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp","source":"ChartMill","related":"RVTY","summary":"Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Thursday and stay ahead of the market trends.","category":"company","datetime":1791470101,"headline":"Which S&P500 stocks are gapping on Thursday?"}, {"id":142693767,"url":"https://finnhub.io/api/news?id=b58fc40ae5e598dea8cde16f52126f564cf1c2ee3879ed84982d201a4a9383d5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"281-Page Report Tracks Post-Pandemic Research Growth Across Pharma, Research and Industry/Cosmetic Users as 3D Assays, Automation and Immuno-oncology Reshape Drug DiscoveryDublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- \"Cell-Based Assay & High Content Screening Market 2025-2029 - Forecasts by User and Product, with Executive and Consultant Guides\" has been added to ResearchAndMarkets.com's offering. Research and Markets has published Cell-Based Assay & High Content Screening Market 2025-2029 - Foreca","category":"company","datetime":1791373560,"headline":"Cell-Based Assay & High Content Screening Market Report Reveals Why Technology Is Outpacing the Market, Profiling Thermo Fisher, Roche, Sartorius, Revvity & 50 Other Key Players"}, {"id":142728288,"url":"https://finnhub.io/api/news?id=8d9b36bda25cc3dae2a96a864dce6dd65b5b0892657a362c9ee1d7be1a2a3179","image":"","source":"Benzinga","related":"RVTY","summary":"Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and raises the price target from $115 to $160.","category":"company","datetime":1791372093,"headline":"Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $160"}, {"id":142697475,"url":"https://finnhub.io/api/news?id=5293fb6cb9cd661ac9f7d6788a377cca7b6432efc60ab2ab7a30c515d13e581b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity will release its third-quarter earnings next month, and analysts anticipate a high single-digit bottom-line growth.","category":"company","datetime":1791363263,"headline":"Revvity Earnings Preview: What to Expect"}, {"id":142694619,"url":"https://finnhub.io/api/news?id=1ca703b7fad07089c730aef2b5ff799b55d0fa3971297d860aacc4957655612f","image":"","source":"Benzinga","related":"RVTY","summary":"William Blair analyst Matt Larew initiates coverage on Revvity (NYSE:RVTY) with a Outperform rating.","category":"company","datetime":1791303270,"headline":"William Blair Initiates Coverage On Revvity with Outperform Rating"}, {"id":142694620,"url":"https://finnhub.io/api/news?id=947600016a722f37a30f498b8ac2a29d931f9e0e2fe0b9640f578c701ecc477d","image":"https://cdn.benzinga.com/files/images/story/2026/10/06/Revvity-Inc.jpg?width=2048&height=1536","source":"Benzinga","related":"RVTY","summary":"William Blair initiates Revvity (RVTY) at Outperform, citing AI tailwinds, life sciences recovery, and potential 20%+ stock upside.","category":"company","datetime":1791298272,"headline":"Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20%"}, {"id":142663473,"url":"https://finnhub.io/api/news?id=77771d918fee3d8e31646d64918184c9a6dda8db8f26fbdf378ad0829d4dcbf5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"WALTHAM, Mass., October 06, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.","category":"company","datetime":1791288000,"headline":"Revvity to Host Investor Day"}, {"id":142592011,"url":"https://finnhub.io/api/news?id=1354c9a3ac86acca82d61b1988ec9d31e1f0743e2810cf95605e1c46072883de","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).","category":"company","datetime":1790953202,"headline":"Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?"}, {"id":142588838,"url":"https://finnhub.io/api/news?id=20f528af1e1b120c026025dfda2cdf1c613fc223627e530195c33ed1dffc0e4d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"WALTHAM, Mass., October 02, 2026--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.","category":"company","datetime":1790942400,"headline":"Revvity to Hold Earnings Call on November 3, 2026"}, {"id":142521568,"url":"https://finnhub.io/api/news?id=8796fb4f75396d1828b23a3b1b8c40d67fff4a675fd7b4ca8feac4460090c598","image":"https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp","source":"ChartMill","related":"RVTY","summary":"Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.","category":"company","datetime":1790787900,"headline":"Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session."}, {"id":142499577,"url":"https://finnhub.io/api/news?id=ff4832de7ba97e9983ed854de2a013c27c693bf0523e62c4715efc273d08445c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.","category":"company","datetime":1790700002,"headline":"Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?"}, {"id":142498306,"url":"https://finnhub.io/api/news?id=b99b47066bf1db0d53f43dfd46ad34ae8002db612643d2fa307c56c3e05fdaf9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.","category":"company","datetime":1790687520,"headline":"Here's Why You Should Retain Revvity Stock in Your Portfolio for Now"}, {"id":142463267,"url":"https://finnhub.io/api/news?id=fc9a13a952922c8e6a07e852b9dc7e22771cf21ad57968453bc3b6669662339b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.","category":"company","datetime":1790586156,"headline":"1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds"}, {"id":142423965,"url":"https://finnhub.io/api/news?id=a9ff4d3ba263b75cc7992bb9bb5763803e41a2e984ca6e0e139ac9d5b22bbd62","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.","category":"company","datetime":1790341740,"headline":"RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection"}, {"id":142423581,"url":"https://finnhub.io/api/news?id=6c773b4b4fd56046165f9f939d6d09120e989435edcb977079470afccf6c629d","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536","source":"Benzinga","related":"RVTY","summary":"Revvity (NYSE:RVTY) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below.\nThis content is powered by Benzinga APIs. For","category":"company","datetime":1790313777,"headline":"Full Transcript: Revvity Q2 2026 Earnings Call"}, {"id":142385877,"url":"https://finnhub.io/api/news?id=0a10ab9058f099ea9dd8fed3a27d11f516b03ecf689b3ca7ecb544bfc4264f7b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9","category":"company","datetime":1790280084,"headline":"Sector Update: Healthcare Stocks Advance Late Afternoon"}, {"id":142385317,"url":"https://finnhub.io/api/news?id=f6f2a26b9f5647288b5da04eda91284fe1679478b8b585e97013ed1ba637efe8","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"RVTY","summary":"Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.","category":"company","datetime":1790276701,"headline":"Discover which S&P500 stocks are making waves on Thursday."}, {"id":142423582,"url":"https://finnhub.io/api/news?id=dbcf2dda78e5857b21e4ffb41aceed01250ceb475132a6bb612a945f2768a415","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536","source":"Benzinga","related":"RVTY","summary":"Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.72%. Currently, Revvity has a market capitalization of $16.82 billion.","category":"company","datetime":1790271929,"headline":"Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years"}, {"id":142384739,"url":"https://finnhub.io/api/news?id=064fca65c12d5a6a144b02ffa288fa39c2b8d29421fbe717d8ae80b17cdacb6f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"All three major US stock indexes fell in late-morning trading Thursday amid uncertainty in the Middl","category":"company","datetime":1790265971,"headline":"Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test"}, {"id":142374834,"url":"https://finnhub.io/api/news?id=57a218c79f8db9c5829dc0b25bcf5d3d5d2d104a3cb88128bac31f9d804f3aa9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"WALTHAM, Mass., September 24, 2026--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear.","category":"company","datetime":1790251200,"headline":"Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes"}, {"id":142379627,"url":"https://finnhub.io/api/news?id=6f5fae7103718fad61d71f792ffe7fcab9e945543672660195665d850dedefdd","image":"","source":"Benzinga","related":"RVTY","summary":"Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that","category":"company","datetime":1790237027,"headline":"Revvity Rolls Out GSP T1D 3plex Kit"}, {"id":142363351,"url":"https://finnhub.io/api/news?id=08e21debb549e8d7bd2c4b8c5893e45852ed71ecc7711b290ef91bf21303ffcf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity has notably outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.","category":"company","datetime":1790159593,"headline":"Is Revvity Stock Outperforming the Dow?"}, {"id":142350477,"url":"https://finnhub.io/api/news?id=cb58c8c8f2b541bcd7567cd8dc86f2dd0998a2a24d9e4da3258e8a9c57c37605","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...","category":"company","datetime":1790129530,"headline":"Why Revvity (RVTY) Is Getting Attention Today"}, {"id":142328474,"url":"https://finnhub.io/api/news?id=85efb7d8043da2785c44589fe07e464369b52343ea3a62c863b956ea862cb220","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Label-Free Detection - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4","category":"company","datetime":1790065560,"headline":"Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030"}, {"id":142328487,"url":"https://finnhub.io/api/news?id=293df837bbb17c71cf269b411ac0010b830920bae67dc70e20edcee04009550a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"High Content Screening (HCS) - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing","category":"company","datetime":1790065140,"headline":"Capitalize on High Content Screening Disruption: Decode How Thermo Fisher Scientific, Danaher, Revvity, and Yokogawa Are Reshaping Global R&D ROI and Revenue"}, {"id":142269870,"url":"https://finnhub.io/api/news?id=97da2091fb37a98868cc4df2c623e9c31db2fd3283341dda1e7fd6b0739faf09","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149954800/image_2149954800.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"RVTY","summary":"U.S. stocks closed the week mixed as Treasury yields rose amid a Fed rate hike, and fears of AI development grew. Read more about this week's top events on Wall Street.","category":"company","datetime":1789800247,"headline":"What Moved Markets This Week"}, {"id":142270772,"url":"https://finnhub.io/api/news?id=2fbac1a765a47bf212e99e40ad93c0b49a5ff423030f1a4db735d13f67e98fb2","image":"https://cdn.benzinga.com/files/images/story/2026/09/18/Diesel-Prices-Cross-6.jpg?width=2048&height=1536","source":"Benzinga","related":"RVTY","summary":"The Fed hiked for the first time since 2023; the 10-year yield touched 5.04%, and record diesel prices hit truckers and automakers.","category":"company","datetime":1789747909,"headline":"Fed Raises Rates, Yields Hit 2007 Highs as Fuel Costs Set Records: This Week On Wall Street"}, {"id":142249608,"url":"https://finnhub.io/api/news?id=713a37af216447ec3bd78a404d516aab7a7639f9e3cf8a77d99b3839d2ffcb44","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.","category":"company","datetime":1789719440,"headline":"1 Momentum Stock with Promising Prospects and 2 Facing Headwinds"}, {"id":142198959,"url":"https://finnhub.io/api/news?id=568783958075196b65740530debea12cb32f6534984a1b55719ef4f7c7471b7c","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"RVTY","summary":"Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.","category":"company","datetime":1789585501,"headline":"Explore the top gainers and losers within the S&P500 index in today's session."}, {"id":142188758,"url":"https://finnhub.io/api/news?id=03b1bbe1a346d39ced2120c20af628767c205f491c25a175a480c992424683c9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.","category":"company","datetime":1789550040,"headline":"Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?"}, {"id":142167113,"url":"https://finnhub.io/api/news?id=b9533ba462e02bc4cdd69ebe009cce3b112c1338397a301218653d5b059ea426","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"RVTY","summary":"Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.","category":"company","datetime":1789499101,"headline":"Discover which S&P500 stocks are making waves on Tuesday."}, {"id":142162217,"url":"https://finnhub.io/api/news?id=c9e230170d179b85b200d044ccc0f27596b9851ed1649e5e94f0dc70a6ee1f7d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.","category":"company","datetime":1789479331,"headline":"Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks"}, {"id":142194774,"url":"https://finnhub.io/api/news?id=d1cab808ccf45cf13f1263e44cacc1adc587155103fca3659b6bbe4aa4db95f1","image":"https://cdn.benzinga.com/files/images/story/2026/09/15/Stock-Market-Graph-Crashing-Down--Wall-S.jpg?width=2048&height=1536","source":"Benzinga","related":"RVTY","summary":"The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.","category":"company","datetime":1789478829,"headline":"10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today"}, {"id":142165183,"url":"https://finnhub.io/api/news?id=41ebfd4b80544d2c7c619a56a61cee031e3049ed69310da56b5dd1c7a7151515","image":"https://image.cnbcfm.com/api/v1/image/108326254-1782318177071-gettyimages-2213364616-img_9901.jpeg?v=1782318352&w=1920&h=1080","source":"CNBC","related":"RVTY","summary":"These are the stocks posting the largest moves midday.","category":"company","datetime":1789473808,"headline":"Stocks making the biggest moves midday: Skyworks Solutions, Axon, Dave & Buster's, Revvity & more"}, {"id":142164499,"url":"https://finnhub.io/api/news?id=a187851a3b32d0f518cf6a22cdf7cb457662bd37fcebf1db3d2d732edf49b488","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"RVTY","summary":"Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...","category":"company","datetime":1789473097,"headline":"Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript"}, {"id":142195468,"url":"https://finnhub.io/api/news?id=84be75a7fa25fb4e6b70806a85064079868a4c59df9eb73aed8b3ebb3fbe2245","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent","category":"company","datetime":1789402620,"headline":"VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space."}, {"id":142139504,"url":"https://finnhub.io/api/news?id=892ee473a89448e463e9ebabbdd3627fdd3c2e2cad825c716923497669bcd3f3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.","category":"company","datetime":1789399410,"headline":"3 Healthcare Stocks That Fall Short"}, {"id":142138505,"url":"https://finnhub.io/api/news?id=69174abc8d26e7ed40432acacd43de7ef7c90e09eac260583ae38c53c0592293","image":"","source":"SeekingAlpha","related":"RVTY","summary":"","category":"company","datetime":1789385497,"headline":"Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"}, {"id":142087303,"url":"https://finnhub.io/api/news?id=ccd73376aab39d765a0ae9080eecae78d1cc12a45b23ff5dbdcee5c0d0633f93","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.","category":"company","datetime":1789139940,"headline":"Revvity to Acquire Human Cell Design to Boost Metabolic Discovery"}, {"id":142025419,"url":"https://finnhub.io/api/news?id=26ba77f1d5d5d1d933db3ca05680140c3536502285a122c8a8b36cdf9f7d1322","image":"https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp","source":"ChartMill","related":"RVTY","summary":"Let's have a look at the S&P500 gap up and gap down stocks in today's session.","category":"company","datetime":1788964501,"headline":"These S&P500 stocks are gapping in today's session"}, {"id":142026577,"url":"https://finnhub.io/api/news?id=cb092d0177c73ef991e01bd2f9b86bc6b770d0cc8355a7025df5d92b2dc0bbcc","image":"","source":"SeekingAlpha","related":"RVTY","summary":"","category":"company","datetime":1788958626,"headline":"Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript"}, {"id":142007727,"url":"https://finnhub.io/api/news?id=c1105d1e4e608643a2f4b83f95153adcb96bcc32f5073d0146317266dabca956","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"WALTHAM, Mass., September 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, includin","category":"company","datetime":1788948000,"headline":"Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery"}, {"id":142026253,"url":"https://finnhub.io/api/news?id=14a165ee3da6cf1e87cced8f93e5010791421eec4a891b5f0776077838aedbf3","image":"","source":"Benzinga","related":"RVTY","summary":"UBS analyst Doug Schenkel assumes Revvity (NYSE:RVTY) with a Neutral rating and raises Price Target to $140.","category":"company","datetime":1788947825,"headline":"UBS Assumes Revvity at Neutral, Raises Price Target to $140"}, {"id":142026254,"url":"https://finnhub.io/api/news?id=afa5a4ecb2479e8eee511d8473093253608857e03a715a73a0bd02872012e9a4","image":"https://cdn.benzinga.com/files/images/story/2026/09/09/Revvity-Inc.jpg?width=2048&height=1536","source":"Benzinga","related":"RVTY","summary":"Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.","category":"company","datetime":1788946529,"headline":"Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition"}, {"id":142026255,"url":"https://finnhub.io/api/news?id=c0e3abf1a20772b3a6ef5ac36a02a5c40065dd69d9c3e39cefaa9ae53e03f69c","image":"","source":"Benzinga","related":"RVTY","summary":" The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other","category":"company","datetime":1788934162,"headline":"Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases"}, {"id":141950366,"url":"https://finnhub.io/api/news?id=9ffbefa46ae6a3e4ca32751051e8d41fdf4e5c7ea74772461a6e2e856ea0ded6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro","category":"company","datetime":1788878940,"headline":"Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 2
recomputed_at_score true
sentiment_score_raw 0.6
source_article_count 46
discarded_article_count 37
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 2.4 5/110 48% 2.4
資金流 13.2 20/110 66% 13.2
市場環境 10.8 15/110 72% 10.8
催化劑 2 20/110 10% 2
風險管理 5.7 10/110 57% 5.7
技術信號 18.4 30/110 61.33% 18.4
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 4/50
ret_5d 0.0208
max_score 50
max_total 50
raw_total 4
vcp_bonus 0
vol_ratio 0.6205
ret_points 4
vol_points 0
range_ratio 0.9304
volat_points 0
day_range_pct 0.0372
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 0
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Elevated
reason risk management score >= 5/10

position

score 1.1

details

atrPct 4.0521
turnoverUsdM 221.6819
liquidityPoints 0.4
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.RVTY
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 139.8286

strength_details

ma_score 1.5
atr_score 1
rsi_score 3
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 8.1
take_profit_price 164.8511
target_multiplier 1.9
technical_strength 1.63
take_profit_percent 8.3
positionPoints 1.1
stopLossPoints 1.2

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 8.1042
diversificationPoints 2

Calculation audit log

基本面分析總分: 2.4/5分
資金流分析總分: 13.2/20分
市場環境分析總分: 10.8/15分
催化劑分析: 2/20分
風險管理總分: 5.7/10分
技術信號分析總分: 18.4/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 78.57
atr
atr 6.1657
rule ATR / current price; lower volatility scores higher
score 4
atr_pct 4.05
cci
rule Cursor_18.24 CCI bands
level 平衡
score 6
value 43.91
cmf
rule Cursor_18.24 CMF bands
level 輕微流入
score 6
value 0.1274
kdj
d 61.1
j 18.19
k 46.8
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 平衡
score 6
value 57.65
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 6
trend 有流入
value 15242700
recentSlope 295650
previousSlope 985220
rsi
value 64.27
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 150.6675
position SAR喺價下
distancePct 0.98
previousTrend 上升
ma50
value 131.2764
macd
macd 6.773
trend 中性偏多
signal 7.0537
histogram -0.2807
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 146.552
position 連續5日>VWAP
consecutiveAbove 19
volume
rule Cursor_18.24 volume ratio
level 空升
ratio 0.62
score 2
avgVolume 2353670
currentVolume 1456900
derived
ma20 146.6695
ma50 131.2764
prevClose 153.6
avgVolume10 2113580
avgVolume20 2353670
changePercent -0.94
avgVolumeForScore 2353670
ma_cross
ma20 146.6695
ma50 131.2764
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 145.1085
prevMa50 130.5006
spreadPct 11.73
isVolumeBreakout false
bollinger
lower 130.4113
upper 162.9277
position 上半部
rsi_short
value 47.96
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.62

Raw calculation JSON

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 4.052116193480547,
        "turnoverUsdM": 221.681904,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.RVTY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 139.8286,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 3,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 8.1,
      "take_profit_price": 164.8511,
      "target_multiplier": 1.9,
      "technical_strength": 1.63,
      "take_profit_percent": 8.3
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 8.104232386961094,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 60.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 56.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 146.6695,
    "ma50": 131.2764,
    "close": 152.16,
    "prevClose": 153.6,
    "avgVolume20": 2353670,
    "volumeRatio": 0.62,
    "changePercent": -0.94
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": 0.020797008195317268,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 0.6204789131291192,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.9304163656972562,
      "volat_points": 0,
      "day_range_pct": 0.0371977523659306,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 60.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 48,
        "contribution": 2.4
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 10.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 72,
        "contribution": 10.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 57,
        "contribution": 5.7
      },
      {
        "raw": 18.4,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 61.33,
        "contribution": 18.4
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 56.5,
    "details": [
      "基本面分析總分: 2.4/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 10.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.7/10分",
      "技術信號分析總分: 18.4/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.4,
      "資金流": 13.2,
      "市場環境": 10.8,
      "情緒分析": 4,
      "技術信號": 18.4,
      "風險管理": 5.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 221.681904,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 2.4,
          "obvPoints": 2.4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.RVTY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.08
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 735.7219992500001,
                "ma50": 723.1690000399999,
                "name": "QQQ",
                "close": 747.58002,
                "points": 2
              },
              "spy": {
                "ma20": 767.26299675,
                "ma50": 766.83679764,
                "name": "SPY",
                "close": 773.92999,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 4.052116193480547,
          "atrPoints": 2,
          "cciPoints": 2.4,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142592011,
                "url": "https://finnhub.io/api/news?id=1354c9a3ac86acca82d61b1988ec9d31e1f0743e2810cf95605e1c46072883de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1790953202,
                "headline": "Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?"
              },
              {
                "id": 142499577,
                "url": "https://finnhub.io/api/news?id=ff4832de7ba97e9983ed854de2a013c27c693bf0523e62c4715efc273d08445c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1790700002,
                "headline": "Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?"
              },
              {
                "id": 142423965,
                "url": "https://finnhub.io/api/news?id=a9ff4d3ba263b75cc7992bb9bb5763803e41a2e984ca6e0e139ac9d5b22bbd62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.",
                "category": "company",
                "datetime": 1790341740,
                "headline": "RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection"
              },
              {
                "id": 142350477,
                "url": "https://finnhub.io/api/news?id=cb58c8c8f2b541bcd7567cd8dc86f2dd0998a2a24d9e4da3258e8a9c57c37605",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...",
                "category": "company",
                "datetime": 1790129530,
                "headline": "Why Revvity (RVTY) Is Getting Attention Today"
              },
              {
                "id": 142188758,
                "url": "https://finnhub.io/api/news?id=03b1bbe1a346d39ced2120c20af628767c205f491c25a175a480c992424683c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1789550040,
                "headline": "Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?"
              },
              {
                "id": 142162217,
                "url": "https://finnhub.io/api/news?id=c9e230170d179b85b200d044ccc0f27596b9851ed1649e5e94f0dc70a6ee1f7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.",
                "category": "company",
                "datetime": 1789479331,
                "headline": "Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks"
              },
              {
                "id": 142164499,
                "url": "https://finnhub.io/api/news?id=a187851a3b32d0f518cf6a22cdf7cb457662bd37fcebf1db3d2d732edf49b488",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...",
                "category": "company",
                "datetime": 1789473097,
                "headline": "Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript"
              },
              {
                "id": 142138505,
                "url": "https://finnhub.io/api/news?id=69174abc8d26e7ed40432acacd43de7ef7c90e09eac260583ae38c53c0592293",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1789385497,
                "headline": "Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              }
            ],
            "raw_source": [
              {
                "id": 142728921,
                "url": "https://finnhub.io/api/news?id=0dd7d1b383dd91d4ef55e272b4d0e25c1c563ddef68dfa481dcf459a3f0016fa",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Thursday and stay ahead of the market trends.",
                "category": "company",
                "datetime": 1791470101,
                "headline": "Which S&P500 stocks are gapping on Thursday?"
              },
              {
                "id": 142693767,
                "url": "https://finnhub.io/api/news?id=b58fc40ae5e598dea8cde16f52126f564cf1c2ee3879ed84982d201a4a9383d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "281-Page Report Tracks Post-Pandemic Research Growth Across Pharma, Research and Industry/Cosmetic Users as 3D Assays, Automation and Immuno-oncology Reshape Drug DiscoveryDublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- \"Cell-Based Assay & High Content Screening Market 2025-2029 - Forecasts by User and Product, with Executive and Consultant Guides\" has been added to ResearchAndMarkets.com's offering. Research and Markets has published Cell-Based Assay & High Content Screening Market 2025-2029 - Foreca",
                "category": "company",
                "datetime": 1791373560,
                "headline": "Cell-Based Assay & High Content Screening Market Report Reveals Why Technology Is Outpacing the Market, Profiling Thermo Fisher, Roche, Sartorius, Revvity & 50 Other Key Players"
              },
              {
                "id": 142728288,
                "url": "https://finnhub.io/api/news?id=8d9b36bda25cc3dae2a96a864dce6dd65b5b0892657a362c9ee1d7be1a2a3179",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Barclays  analyst Luke Sergott   maintains Revvity (NYSE:RVTY) with a Equal-Weight and raises the price target from $115 to $160.",
                "category": "company",
                "datetime": 1791372093,
                "headline": "Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $160"
              },
              {
                "id": 142697475,
                "url": "https://finnhub.io/api/news?id=5293fb6cb9cd661ac9f7d6788a377cca7b6432efc60ab2ab7a30c515d13e581b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity will release its third-quarter earnings next month, and analysts anticipate a high single-digit bottom-line growth.",
                "category": "company",
                "datetime": 1791363263,
                "headline": "Revvity Earnings Preview: What to Expect"
              },
              {
                "id": 142694619,
                "url": "https://finnhub.io/api/news?id=1ca703b7fad07089c730aef2b5ff799b55d0fa3971297d860aacc4957655612f",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "William Blair  analyst Matt Larew   initiates coverage on Revvity (NYSE:RVTY) with a Outperform rating.",
                "category": "company",
                "datetime": 1791303270,
                "headline": "William Blair Initiates Coverage On Revvity with Outperform Rating"
              },
              {
                "id": 142694620,
                "url": "https://finnhub.io/api/news?id=947600016a722f37a30f498b8ac2a29d931f9e0e2fe0b9640f578c701ecc477d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/06/Revvity-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "William Blair initiates Revvity (RVTY) at Outperform, citing AI tailwinds, life sciences recovery, and potential 20%+ stock upside.",
                "category": "company",
                "datetime": 1791298272,
                "headline": "Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20%"
              },
              {
                "id": 142663473,
                "url": "https://finnhub.io/api/news?id=77771d918fee3d8e31646d64918184c9a6dda8db8f26fbdf378ad0829d4dcbf5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., October 06, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.",
                "category": "company",
                "datetime": 1791288000,
                "headline": "Revvity to Host Investor Day"
              },
              {
                "id": 142592011,
                "url": "https://finnhub.io/api/news?id=1354c9a3ac86acca82d61b1988ec9d31e1f0743e2810cf95605e1c46072883de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1790953202,
                "headline": "Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?"
              },
              {
                "id": 142588838,
                "url": "https://finnhub.io/api/news?id=20f528af1e1b120c026025dfda2cdf1c613fc223627e530195c33ed1dffc0e4d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., October 02, 2026--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.",
                "category": "company",
                "datetime": 1790942400,
                "headline": "Revvity to Hold Earnings Call on November 3, 2026"
              },
              {
                "id": 142521568,
                "url": "https://finnhub.io/api/news?id=8796fb4f75396d1828b23a3b1b8c40d67fff4a675fd7b4ca8feac4460090c598",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.",
                "category": "company",
                "datetime": 1790787900,
                "headline": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session."
              },
              {
                "id": 142499577,
                "url": "https://finnhub.io/api/news?id=ff4832de7ba97e9983ed854de2a013c27c693bf0523e62c4715efc273d08445c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1790700002,
                "headline": "Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?"
              },
              {
                "id": 142498306,
                "url": "https://finnhub.io/api/news?id=b99b47066bf1db0d53f43dfd46ad34ae8002db612643d2fa307c56c3e05fdaf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.",
                "category": "company",
                "datetime": 1790687520,
                "headline": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now"
              },
              {
                "id": 142463267,
                "url": "https://finnhub.io/api/news?id=fc9a13a952922c8e6a07e852b9dc7e22771cf21ad57968453bc3b6669662339b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1790586156,
                "headline": "1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds"
              },
              {
                "id": 142423965,
                "url": "https://finnhub.io/api/news?id=a9ff4d3ba263b75cc7992bb9bb5763803e41a2e984ca6e0e139ac9d5b22bbd62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.",
                "category": "company",
                "datetime": 1790341740,
                "headline": "RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection"
              },
              {
                "id": 142423581,
                "url": "https://finnhub.io/api/news?id=6c773b4b4fd56046165f9f939d6d09120e989435edcb977079470afccf6c629d",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity (NYSE:RVTY) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below.\nThis content is powered by Benzinga APIs. For",
                "category": "company",
                "datetime": 1790313777,
                "headline": "Full Transcript: Revvity Q2 2026 Earnings Call"
              },
              {
                "id": 142385877,
                "url": "https://finnhub.io/api/news?id=0a10ab9058f099ea9dd8fed3a27d11f516b03ecf689b3ca7ecb544bfc4264f7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9",
                "category": "company",
                "datetime": 1790280084,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 142385317,
                "url": "https://finnhub.io/api/news?id=f6f2a26b9f5647288b5da04eda91284fe1679478b8b585e97013ed1ba637efe8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1790276701,
                "headline": "Discover which S&P500 stocks are making waves on Thursday."
              },
              {
                "id": 142423582,
                "url": "https://finnhub.io/api/news?id=dbcf2dda78e5857b21e4ffb41aceed01250ceb475132a6bb612a945f2768a415",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.72%. Currently, Revvity has a market capitalization of $16.82 billion.",
                "category": "company",
                "datetime": 1790271929,
                "headline": "Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years"
              },
              {
                "id": 142384739,
                "url": "https://finnhub.io/api/news?id=064fca65c12d5a6a144b02ffa288fa39c2b8d29421fbe717d8ae80b17cdacb6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "All three major US stock indexes fell in late-morning trading Thursday amid uncertainty in the Middl",
                "category": "company",
                "datetime": 1790265971,
                "headline": "Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test"
              },
              {
                "id": 142374834,
                "url": "https://finnhub.io/api/news?id=57a218c79f8db9c5829dc0b25bcf5d3d5d2d104a3cb88128bac31f9d804f3aa9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., September 24, 2026--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear.",
                "category": "company",
                "datetime": 1790251200,
                "headline": "Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes"
              },
              {
                "id": 142379627,
                "url": "https://finnhub.io/api/news?id=6f5fae7103718fad61d71f792ffe7fcab9e945543672660195665d850dedefdd",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that",
                "category": "company",
                "datetime": 1790237027,
                "headline": "Revvity Rolls Out GSP T1D 3plex Kit"
              },
              {
                "id": 142363351,
                "url": "https://finnhub.io/api/news?id=08e21debb549e8d7bd2c4b8c5893e45852ed71ecc7711b290ef91bf21303ffcf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has notably outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1790159593,
                "headline": "Is Revvity Stock Outperforming the Dow?"
              },
              {
                "id": 142350477,
                "url": "https://finnhub.io/api/news?id=cb58c8c8f2b541bcd7567cd8dc86f2dd0998a2a24d9e4da3258e8a9c57c37605",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...",
                "category": "company",
                "datetime": 1790129530,
                "headline": "Why Revvity (RVTY) Is Getting Attention Today"
              },
              {
                "id": 142328474,
                "url": "https://finnhub.io/api/news?id=85efb7d8043da2785c44589fe07e464369b52343ea3a62c863b956ea862cb220",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Label-Free Detection - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4",
                "category": "company",
                "datetime": 1790065560,
                "headline": "Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030"
              },
              {
                "id": 142328487,
                "url": "https://finnhub.io/api/news?id=293df837bbb17c71cf269b411ac0010b830920bae67dc70e20edcee04009550a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"High Content Screening (HCS) - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing",
                "category": "company",
                "datetime": 1790065140,
                "headline": "Capitalize on High Content Screening Disruption: Decode How Thermo Fisher Scientific, Danaher, Revvity, and Yokogawa Are Reshaping Global R&D ROI and Revenue"
              },
              {
                "id": 142269870,
                "url": "https://finnhub.io/api/news?id=97da2091fb37a98868cc4df2c623e9c31db2fd3283341dda1e7fd6b0739faf09",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149954800/image_2149954800.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "U.S. stocks closed the week mixed as Treasury yields rose amid a Fed rate hike, and fears of AI development grew. Read more about this week's top events on Wall Street.",
                "category": "company",
                "datetime": 1789800247,
                "headline": "What Moved Markets This Week"
              },
              {
                "id": 142270772,
                "url": "https://finnhub.io/api/news?id=2fbac1a765a47bf212e99e40ad93c0b49a5ff423030f1a4db735d13f67e98fb2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/18/Diesel-Prices-Cross-6.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "The Fed hiked for the first time since 2023; the 10-year yield touched 5.04%, and record diesel prices hit truckers and automakers.",
                "category": "company",
                "datetime": 1789747909,
                "headline": "Fed Raises Rates, Yields Hit 2007 Highs as Fuel Costs Set Records: This Week On Wall Street"
              },
              {
                "id": 142249608,
                "url": "https://finnhub.io/api/news?id=713a37af216447ec3bd78a404d516aab7a7639f9e3cf8a77d99b3839d2ffcb44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.",
                "category": "company",
                "datetime": 1789719440,
                "headline": "1 Momentum  Stock with Promising Prospects and 2 Facing Headwinds"
              },
              {
                "id": 142198959,
                "url": "https://finnhub.io/api/news?id=568783958075196b65740530debea12cb32f6534984a1b55719ef4f7c7471b7c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1789585501,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 142188758,
                "url": "https://finnhub.io/api/news?id=03b1bbe1a346d39ced2120c20af628767c205f491c25a175a480c992424683c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1789550040,
                "headline": "Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?"
              },
              {
                "id": 142167113,
                "url": "https://finnhub.io/api/news?id=b9533ba462e02bc4cdd69ebe009cce3b112c1338397a301218653d5b059ea426",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1789499101,
                "headline": "Discover which S&P500 stocks are making waves on Tuesday."
              },
              {
                "id": 142162217,
                "url": "https://finnhub.io/api/news?id=c9e230170d179b85b200d044ccc0f27596b9851ed1649e5e94f0dc70a6ee1f7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.",
                "category": "company",
                "datetime": 1789479331,
                "headline": "Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks"
              },
              {
                "id": 142194774,
                "url": "https://finnhub.io/api/news?id=d1cab808ccf45cf13f1263e44cacc1adc587155103fca3659b6bbe4aa4db95f1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/15/Stock-Market-Graph-Crashing-Down--Wall-S.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.",
                "category": "company",
                "datetime": 1789478829,
                "headline": "10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today"
              },
              {
                "id": 142165183,
                "url": "https://finnhub.io/api/news?id=41ebfd4b80544d2c7c619a56a61cee031e3049ed69310da56b5dd1c7a7151515",
                "image": "https://image.cnbcfm.com/api/v1/image/108326254-1782318177071-gettyimages-2213364616-img_9901.jpeg?v=1782318352&w=1920&h=1080",
                "source": "CNBC",
                "related": "RVTY",
                "summary": "These are the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1789473808,
                "headline": "Stocks making the biggest moves midday: Skyworks Solutions, Axon, Dave & Buster's, Revvity & more"
              },
              {
                "id": 142164499,
                "url": "https://finnhub.io/api/news?id=a187851a3b32d0f518cf6a22cdf7cb457662bd37fcebf1db3d2d732edf49b488",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...",
                "category": "company",
                "datetime": 1789473097,
                "headline": "Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript"
              },
              {
                "id": 142195468,
                "url": "https://finnhub.io/api/news?id=84be75a7fa25fb4e6b70806a85064079868a4c59df9eb73aed8b3ebb3fbe2245",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent",
                "category": "company",
                "datetime": 1789402620,
                "headline": "VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space."
              },
              {
                "id": 142139504,
                "url": "https://finnhub.io/api/news?id=892ee473a89448e463e9ebabbdd3627fdd3c2e2cad825c716923497669bcd3f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.",
                "category": "company",
                "datetime": 1789399410,
                "headline": "3 Healthcare Stocks That Fall Short"
              },
              {
                "id": 142138505,
                "url": "https://finnhub.io/api/news?id=69174abc8d26e7ed40432acacd43de7ef7c90e09eac260583ae38c53c0592293",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1789385497,
                "headline": "Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142087303,
                "url": "https://finnhub.io/api/news?id=ccd73376aab39d765a0ae9080eecae78d1cc12a45b23ff5dbdcee5c0d0633f93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.",
                "category": "company",
                "datetime": 1789139940,
                "headline": "Revvity to Acquire Human Cell Design to Boost Metabolic Discovery"
              },
              {
                "id": 142025419,
                "url": "https://finnhub.io/api/news?id=26ba77f1d5d5d1d933db3ca05680140c3536502285a122c8a8b36cdf9f7d1322",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Let's have a look at the S&P500 gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1788964501,
                "headline": "These S&P500 stocks are gapping in today's session"
              },
              {
                "id": 142026577,
                "url": "https://finnhub.io/api/news?id=cb092d0177c73ef991e01bd2f9b86bc6b770d0cc8355a7025df5d92b2dc0bbcc",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1788958626,
                "headline": "Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript"
              },
              {
                "id": 142007727,
                "url": "https://finnhub.io/api/news?id=c1105d1e4e608643a2f4b83f95153adcb96bcc32f5073d0146317266dabca956",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., September 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, includin",
                "category": "company",
                "datetime": 1788948000,
                "headline": "Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery"
              },
              {
                "id": 142026253,
                "url": "https://finnhub.io/api/news?id=14a165ee3da6cf1e87cced8f93e5010791421eec4a891b5f0776077838aedbf3",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "UBS  analyst Doug Schenkel   assumes Revvity (NYSE:RVTY) with a Neutral rating and raises Price Target to $140.",
                "category": "company",
                "datetime": 1788947825,
                "headline": "UBS Assumes Revvity at Neutral, Raises Price Target to $140"
              },
              {
                "id": 142026254,
                "url": "https://finnhub.io/api/news?id=afa5a4ecb2479e8eee511d8473093253608857e03a715a73a0bd02872012e9a4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/09/Revvity-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.",
                "category": "company",
                "datetime": 1788946529,
                "headline": "Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition"
              },
              {
                "id": 142026255,
                "url": "https://finnhub.io/api/news?id=c0e3abf1a20772b3a6ef5ac36a02a5c40065dd69d9c3e39cefaa9ae53e03f69c",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": " The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other",
                "category": "company",
                "datetime": 1788934162,
                "headline": "Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases"
              },
              {
                "id": 141950366,
                "url": "https://finnhub.io/api/news?id=9ffbefa46ae6a3e4ca32751051e8d41fdf4e5c7ea74772461a6e2e856ea0ded6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro",
                "category": "company",
                "datetime": 1788878940,
                "headline": "Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 46,
            "discarded_article_count": 37
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.4,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50;升放量(近10日2日);Ready=N;Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 2159530,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 2221880,
              "avg_vol_20": 2348025,
              "avg_vol_30": 2159530,
              "range_pct_10": 0.16075190588853847,
              "range_pct_20": 0.2980415352260778,
              "range_pct_30": 0.2980415352260778,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.028872023079096,
              "dist_to_20d_high": 0.08475187969924815,
              "down_shrink_days": 1,
              "breakout_level_20d": 166.25,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5393607497243663
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 4.052116193480547,
              "turnoverUsdM": 221.681904,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.RVTY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 139.8286,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 3,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 8.1,
            "take_profit_price": 164.8511,
            "target_multiplier": 1.9,
            "technical_strength": 1.63,
            "take_profit_percent": 8.3
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 8.104232386961094,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 6.1657,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 4.05
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 43.91
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1274
    },
    "kdj": {
      "d": 61.1,
      "j": 18.19,
      "k": 46.8,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 57.65
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 15242700,
      "recentSlope": 295650,
      "previousSlope": 985220
    },
    "rsi": 64.27,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 150.6675,
      "position": "SAR喺價下",
      "distancePct": 0.98,
      "previousTrend": "上升"
    },
    "ma50": 131.2764,
    "macd": {
      "macd": 6.772963828418511,
      "trend": "中性偏多",
      "signal": 7.0536812802088,
      "histogram": -0.28071745179028884
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 146.552,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 19
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.62,
      "score": 2,
      "avgVolume": 2353670,
      "currentVolume": 1456900
    },
    "derived": {
      "ma20": 146.6695,
      "ma50": 131.2764,
      "prevClose": 153.6,
      "avgVolume10": 2113580,
      "avgVolume20": 2353670,
      "changePercent": -0.94,
      "avgVolumeForScore": 2353670
    },
    "ma_cross": {
      "ma20": 146.6695,
      "ma50": 131.2764,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 145.1085,
      "prevMa50": 130.5006,
      "spreadPct": 11.73,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 130.4113,
      "upper": 162.9277,
      "position": "上半部"
    },
    "rsi_short": 47.96,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.62
    }
  }
}

Raw metrics JSON

{
  "close": 152.16,
  "volume": 1456900,
  "changePercent": -0.94
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank provides research support only and does not provide financial advice or buy/sell recommendations.